Department of Medicine, Farwaniya Hospital, Ministry of Health, Kuwait.
East Mediterr Health J. 2011 Aug;17(8):669-78.
Few studies have been conducted in the Eastern Mediterranean region on chronic hepatitis C virus (HCV) infection with reference to genotypes. We investigated the response to standard combination therapy (pegylated interferon/ribavirin) of different genotypes of HCV in Kuwaiti patients and factors that could be associated with sustained virological response (SVR). The records of all Kuwaiti patients treated for chronic HCV between January 2003 and May 2009 were retrospectively identified and reviewed. Of 108 patients studied, 27.8% were infected with genotype 1, 25.0% with genotype 3 and 47.2% with genotype 4. Overall, 64.8% of patients achieved SVR, 25.9%, were non-responders and 9.3% were relapsers. Baseline viral load and alanine aminotransferase level in addition to early virological response to pegylated interferon-based therapy may serve as a decision tool for clinicians to identify patients who are unlikely to achieve SVR.
针对基因型，在地中海东部地区开展的慢性丙型肝炎病毒（HCV）感染研究较少。我们研究了科威特患者对标准联合疗法（聚乙二醇干扰素/利巴韦林）的不同 HCV 基因型的反应，以及可能与持续病毒学应答（SVR）相关的因素。回顾性确定并审查了 2003 年 1 月至 2009 年 5 月期间所有接受慢性 HCV 治疗的科威特患者的记录。在 108 名研究患者中，27.8%感染了基因型 1，25.0%感染了基因型 3，47.2%感染了基因型 4。总的来说，64.8%的患者达到 SVR，25.9%的患者无应答，9.3%的患者复发。基线病毒载量和丙氨酸氨基转移酶水平，以及聚乙二醇干扰素治疗的早期病毒学应答，可作为临床医生识别不太可能达到 SVR 的患者的决策工具。
